Trained Immunity Reprograms Tumor-Associated Myeloid Cells to Overcome Anti-PD-1 Resistance
Biology and Medical Engineering · 10.11.2026 · 2 (1) · 1-32
DOI: 10.63808/bm.v2i1.571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology and Medical Engineering, online erschienen am 10.11.2026. Verfasst von Gang Liu und 1 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study explores whether trained immunity can remodel the tumor immune microenvironment by reprogramming tumor-associated myeloid cells (TAMs) and reverse tumor resistance to anti-PD-1 therapy. An anti-PD-1 resistant tumor model was established, using β-glucan as a trained immunity inducer combined with anti-PD-1 antibody intervention. Single-cell RNA sequencing, flow cytometry, and metabolic analysis were employed to assess TAMs phenotype, antigen presentation capacity, and metabolic reprogramming; in vitro co-culture and in vivo CD8⁺ T cell depletion experiments were used to evaluate myeloid cell-mediated T cell activation and treatment dependency; clinical cohort analyses were combined to explore the relationship between trained immunity-related gene signatures and immune checkpoint therapy response. Trained immunity significantly reshaped TAMs transcriptional profiles and metabolic status, promoting their transformation toward a pro-inflammatory, enhanced antigen-presenting phenotype, while increasing T cell recruitment and activation and reducing immunosuppressive function. In the anti-PD-1 resistant model, trained immunity combined with anti-PD-1 significantly inhibited tumor growth and prolonged survival, with this effect dependent on CD8⁺ T cells and type I interferon signaling. Clinical cohort analysis indicated that high expression of trained immunity-related signatures was associated with better responses to immune checkpoint therapy. Trained immunity can overcome anti-PD-1 resistance by reprogramming tumor-associated myeloid cells, offering a translational potential innate immune intervention strategy to improve immune checkpoint therapy response.
Zitieren
APA
Liu, G., & Wang, J. (2026). Trained Immunity Reprograms Tumor-Associated Myeloid Cells to Overcome Anti-PD-1 Resistance. Biology and Medical Engineering, 2(1), 1-32. https://doi.org/10.63808/bm.v2i1.571
Vancouver
Liu G, Wang J. Trained Immunity Reprograms Tumor-Associated Myeloid Cells to Overcome Anti-PD-1 Resistance. Biology and Medical Engineering. 2026;2(1):1-32. doi:10.63808/bm.v2i1.571
BibTeX
@article{Liu2026,
author = {Liu, Gang and Wang, Jia},
title = {Trained Immunity Reprograms Tumor-Associated Myeloid Cells to Overcome Anti-PD-1 Resistance},
journal = {Biology and Medical Engineering},
year = {2026},
volume = {2},
number = {1},
pages = {1--32},
doi = {10.63808/bm.v2i1.571}
}
EUVIMED